147 related articles for article (PubMed ID: 9857366)
21. [Stem cell therapy for neurodegenerative disorders].
Meyer M; Jensen P; Rasmussen JZ
Ugeskr Laeger; 2010 Sep; 172(38):2604-7. PubMed ID: 20920404
[TBL] [Abstract][Full Text] [Related]
22. Assessing the potential clinical utility of transplantations of neural and mesenchymal stem cells for treating neurodegenerative diseases.
Lescaudron L; Boyer C; Bonnamain V; Fink KD; Lévêque X; Rossignol J; Nerrière-Daguin V; Malouet AC; Lelan F; Dey ND; Michel-Monigadon D; Lu M; Neveu I; von Hörsten S; Naveilhan P; Dunbar GL
Methods Mol Biol; 2012; 879():147-64. PubMed ID: 22610559
[TBL] [Abstract][Full Text] [Related]
23. Immunoprotective sertoli cells: making allogeneic and xenogeneic transplantation feasible.
Mital P; Kaur G; Dufour JM
Reproduction; 2010 Mar; 139(3):495-504. PubMed ID: 19995832
[TBL] [Abstract][Full Text] [Related]
24. Cellular replacement therapy for Parkinson's disease--where we are today?
Redmond DE
Neuroscientist; 2002 Oct; 8(5):457-88. PubMed ID: 12374430
[TBL] [Abstract][Full Text] [Related]
25. Stem cells for neurodegenerative disorders: where can we go from here?
Le Belle JE; Svendsen CN
BioDrugs; 2002; 16(6):389-401. PubMed ID: 12463763
[TBL] [Abstract][Full Text] [Related]
26. Intrastriatal and intranigral grafting of hNT neurons in the 6-OHDA rat model of Parkinson's disease.
Baker KA; Hong M; Sadi D; Mendez I
Exp Neurol; 2000 Apr; 162(2):350-60. PubMed ID: 10739641
[TBL] [Abstract][Full Text] [Related]
27. [Therapeutic potential of fetal neuron grafts in neurodegenerative diseases].
Peschanski M; Hantraye P; Bachoud-Lévi AC; Césaro P
Bull Acad Natl Med; 2000; 184(6):1213-7; discussion 1218-20. PubMed ID: 11268670
[TBL] [Abstract][Full Text] [Related]
28. The future of cell-based transplantation therapies for neurodegenerative disorders.
Lazic SE; Barker RA
J Hematother Stem Cell Res; 2003 Dec; 12(6):635-42. PubMed ID: 14977473
[TBL] [Abstract][Full Text] [Related]
29. Fetal pig neural cells as a restorative therapy for neurodegenerative disease.
Jacoby DB; Lindberg C; Ratliff J; Wunderlich M; Bousquet J; Wetzel K; Beaulieu L; Dinsmore J
Artif Organs; 1997 Nov; 21(11):1192-8. PubMed ID: 9384325
[TBL] [Abstract][Full Text] [Related]
30. The potential of alternate sources of cells for neural grafting in Parkinson's and Huntington's disease.
Drouin-Ouellet J
Neurodegener Dis Manag; 2014; 4(4):297-307. PubMed ID: 25313986
[TBL] [Abstract][Full Text] [Related]
31. Harnessing the immunomodulatory properties of Sertoli cells to enable xenotransplantation in type I diabetes.
Dufour JM; Rajotte RV; Korbutt GS; Emerich DF
Immunol Invest; 2003 Nov; 32(4):275-97. PubMed ID: 14603995
[TBL] [Abstract][Full Text] [Related]
32. Sertoli cells for cell transplantation: pre-clinical studies and future perspectives.
Luca G; Arato I; Sorci G; Cameron DF; Hansen BC; Baroni T; Donato R; White DGJ; Calafiore R
Andrology; 2018 May; 6(3):385-395. PubMed ID: 29600532
[TBL] [Abstract][Full Text] [Related]
33. Enhancement of sensorimotor behavioral recovery in hemiparkinsonian rats with intrastriatal, intranigral, and intrasubthalamic nucleus dopaminergic transplants.
Mukhida K; Baker KA; Sadi D; Mendez I
J Neurosci; 2001 May; 21(10):3521-30. PubMed ID: 11331381
[TBL] [Abstract][Full Text] [Related]
34. Neural transplantation of human neuroteratocarcinoma (hNT) neurons into ischemic rats. A quantitative dose-response analysis of cell survival and behavioral recovery.
Saporta S; Borlongan CV; Sanberg PR
Neuroscience; 1999; 91(2):519-25. PubMed ID: 10366009
[TBL] [Abstract][Full Text] [Related]
35. Terapeutic Potential of Microencapsulated Sertoli Cells in Huntington Disease.
Luca G; Bellezza I; Arato I; Di Pardo A; Mancuso F; Calvitti M; Falabella G; Bartoli S; Maglione V; Amico E; Favellato M; Basta G; Bodo M; Minelli A; Calafiore R; Frati L; Squitieri F
CNS Neurosci Ther; 2016 Aug; 22(8):686-90. PubMed ID: 27225886
[TBL] [Abstract][Full Text] [Related]
36. Survival, neuronal differentiation, and fiber outgrowth of propagated human neural precursor grafts in an animal model of Huntington's disease.
Armstrong RJ; Watts C; Svendsen CN; Dunnett SB; Rosser AE
Cell Transplant; 2000; 9(1):55-64. PubMed ID: 10784067
[TBL] [Abstract][Full Text] [Related]
37. Formation of Sertoli cell-enriched tissue constructs utilizing simulated microgravity technology.
Cameron DF; Hushen JJ; Nazian SJ; Willing A; Saporta S; Sanberg PR
Ann N Y Acad Sci; 2001 Nov; 944():420-8. PubMed ID: 11797690
[TBL] [Abstract][Full Text] [Related]
38. Identification of a specific Sertoli cell marker, Sox9, for use in transplantation.
Hemendinger RA; Gores P; Blacksten L; Harley V; Halberstadt C
Cell Transplant; 2002; 11(6):499-505. PubMed ID: 12428738
[TBL] [Abstract][Full Text] [Related]
39. Fetal allogeneic dopaminergic cell suspension grafts in the ventricular system of the rat: characterization of transplant morphology and graft-host interactions.
Oertel J; Samii M; Walter GF
Acta Neuropathol; 2004 May; 107(5):421-7. PubMed ID: 14872256
[TBL] [Abstract][Full Text] [Related]
40. Transplantation for stroke.
Roitberg B
Neurol Res; 2004 Apr; 26(3):256-64. PubMed ID: 15142317
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
